Low risk High Reward BMRN?

Updated

finds itself at a point of fight or flight, cornered and being pinned below all-time highs and just above the 0.5 retracement level. A lot can be said about this company: battles with the FDA following the Martin Shkreli controversy, having product approval delayed, and dealing with the monotony of the pandemic and the subsequent rise and fall along the way.

Bullish Case - This is a perfect time to scale into a position, anticipating BMRN to become profitable when their drug Roctavian is finally approved and ramps up going into 2024 - 2025. There is an accumulation happening at this level that should bring us to the downtrend, at the very least. Let's see what the level looks like when it surpasses 85.55.

Bearish Case - They are barely profitable. Shouldn't long-term investing involve sound fundamentals? It seems like a lot of hope is invested in the bull case. This is not a discount; it is a warning shot. A warning that will solidify when the 83.51 level collapses like a house of cards built on beach sand. There's no beneficial foundation to support it hitting new highs YTD, suggesting this will end negatively by December.

Conclusion - This is a high-risk, high-reward kind of setup. Granted, if the level holds, this could be extremely beneficial. However, it needs a catalyst to drive investors back. If managed correctly, you can keep losses low if it fails and enjoy considerable success if some good news comes out before the year's end.

Bullish - 85.55
Bearish - 83.51

Note

Still not ready. It is in the accumulation phase at this time.

Note

Still holding off until the break of the downtrend

Note

Took a small position I didn't expect yesterdays explosion to the upside. I plan to cut it in profit and reposition if it still looks good. Gr8 Trade.

JDTheGreat

Sometime you have to take a step back to make a better step forward.

Also on:

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.